2020 saw the growth of Pfizer's leading biosimilars portfolio, allowing patients to access these potentially lower-cost therapies

Globally, there is a growing demand for savings and efficiencies across health care systems. This demand has been emphasized amid an unprecedented global pandemic, driving the need for more accessible and affordable solutions.

Biosimilars can help fill this need. As equally effective and often lower-cost options to their biological medicines, biosimilars can help increase patient access to potentially life-changing therapies and lower the overall cost of care. In fact, estimates show that potential savings from biosimilars range from up to $50 billion over five years to up to $250 billion over 10 years in the five major EU markets and the U.S.^3,4

Pfizer is enthusiastic about the promise of biosimilars and wants to make this promise a reality. For more than 12 years, we have pioneered bringing high-quality biosimilars to patients around the world by applying expertise in biologics, investing significant resources and leveraging our deep understanding of how to navigate regulatory pathways.

In 2020, Pfizer became the first company to launch three oncology monoclonal antibody biosimilars in the U.S., Zirabev™ (bevacizumab-bvzr), Ruxience™ (rituximab-pvvr) and Trazimera™ (trastuzumab-qyyp), offering the medicines at a substantially discounted list price to the originator product. All three are highly similar versions of some of the most widely prescribed oncology therapies, collectively treating nine cancer types.

Pfizer today has the largest biosimilar portfolio in the U.S. and largest oncology biosimilars portfolio globally.^1,2 Now, more than ever, we remain driven to fulfill its promise.